AC Immune SA (NASDAQ:ACIU) Short Interest Up 23.5% in October

AC Immune SA (NASDAQ:ACIU) was the target of a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 984,500 shares, an increase of 23.5% from the October 15th total of 796,900 shares. Currently, 1.6% of the company’s shares are sold short. Based on an average daily volume of 92,100 shares, the short-interest ratio is presently 10.7 days.

AC Immune Stock Down 10.1 %

ACIU opened at $3.19 on Friday. The business has a fifty day moving average of $3.28 and a 200 day moving average of $3.48. The stock has a market cap of $315.62 million, a P/E ratio of -6.93 and a beta of 1.28. AC Immune has a 52-week low of $2.25 and a 52-week high of $5.14.

Institutional Trading of AC Immune

Several institutional investors and hedge funds have recently made changes to their positions in the business. Redmile Group LLC increased its stake in AC Immune by 0.4% in the 1st quarter. Redmile Group LLC now owns 2,007,031 shares of the company’s stock worth $5,941,000 after buying an additional 7,031 shares during the period. China Universal Asset Management Co. Ltd. increased its position in shares of AC Immune by 63.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 19,021 shares of the company’s stock worth $72,000 after acquiring an additional 7,400 shares during the period. BNP Paribas Financial Markets raised its stake in shares of AC Immune by 315.6% during the first quarter. BNP Paribas Financial Markets now owns 11,092 shares of the company’s stock valued at $33,000 after acquiring an additional 8,423 shares in the last quarter. Silverberg Bernstein Capital Management LLC purchased a new stake in shares of AC Immune in the second quarter valued at approximately $40,000. Finally, Lazard Asset Management LLC bought a new position in AC Immune in the first quarter worth approximately $30,000. 51.36% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently issued reports on ACIU. HC Wainwright restated a “buy” rating and issued a $16.00 price target on shares of AC Immune in a research report on Friday. StockNews.com cut shares of AC Immune from a “buy” rating to a “hold” rating in a research note on Tuesday, October 1st.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.